IOL Chemicals
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
IOL Chemicals is navigating a strategic transition from a focus on Ibuprofen to a more diversified portfolio of active pharmaceutical ingredients (APIs) and specialty chemicals. Management's emphasis on operational efficiency and backward integration positions the company to mitigate raw material cost pressures while capitalizing on growth opportunities in high-value APIs like Paracetamol and Metformin. Despite a forecasted revenue contraction, Vista's outlook anticipates margin improvement driven by disciplined capital allocation and enhanced capacity utilization. The company's strong balance sheet, characterized by low leverage, supports its growth initiatives. However, execution risks related to the development of new assets and adherence to global regulatory standards remain critical watchpoints. The Indian API sector's structural growth, bolstered by the 'China+1' strategy, presents a favorable backdrop, although competitive pricing pressures could temper revenue growth. Overall, IOL Chemicals is positioned for long-term value creation, albeit with caution warranted regarding its execution capabilities and market dynamics over the next 12-24 months
Why We Like This Stock
- Management's transition to a diversified API portfolio is expected to drive mid-to-high teen revenue growth and margin expansion
- Strong backward integration provides cost control and supply chain stability, enhancing competitive positioning
- The company's low leverage and disciplined capital allocation support financial stability and growth initiatives
Things To Watch Out For
- Revenue is forecasted to contract, posing challenges to overall financial performance
- Execution risks related to the development of new assets and compliance with stringent global regulations could hinder growth
- Competitive pricing pressures in the API market may limit margin expansion despite operational improvements
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,133 | 2,079 | 2,319 | 2,791 | 2,839 |
| Profit Before Tax (Cr.) | 183 | 138 | 195 | 278 | 272 |
| PBT Margin | 8.6% | 6.6% | 841.8% | 10.0% | 9.6% |
| Net Profit (Cr.) | 145 | 113 | 152 | 218 | 213 |
| Earnings Per Share | 4.9 | 3.9 | 5.2 | 7.4 | 7.3 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company operates through, Chemical and Pharmaceutical segments. The Chemical segment offers ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, and acetic anhydride to food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries. The Pharmaceutical segment provides active pharmaceutical ingredients, such as ibuprofen, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, and paracetamol. Its active pharmaceutical ingredients are used for the treatment of anti-inflammatory, analgesic and antipyretic, anti-diabetic, anti- platelet, anti-cholesterol, anti- convulsant, anti-epileptic, anti-hypertensive, and anti-cholelithic, as well as proton pump inhibitor. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is based in Ludhiana, India.